Typhoid fever is common, serious, and difficult to treat. Globally it affects about 16 million people and causes 600,000 deaths per year, 80% of which occur in Asia. Since Salmonella typhi is frequently resistant to first-line antibiotics, immunization is likely to be the most cost-effective approach to combating typhoid fever. Commercially available typhoid vaccines are not effective in children less than 2 years of age. A lab-based study suggested that typhoid is an important cause of illness in children less than 2 years of age in Bangladesh. Although endemic in Bangladesh, reliable community-based data on the incidence of typhoid fever is not available. This JHSPH, ICDDR,B, and Dhaka Shishu Hospital collaboration is a prospective, community-based surveillance study with the intent of estimating community-based incidence of typhoid fever in children under 5 years of age in Mirzapur, Bangladesh as a prelude to a conjugate typhoid vaccine trial. Principal Investigator: Abdullah Baqui (JHSPH) Co-Principal Investigators: - Shams El Arifeen (ICDDR,B)
- Samir K Saha (Dhaka Shishu Hospital, Bangaldesh)
- Steve Luby (ICDDR,B)
|
